About Globeimmune (OTCMKTS:GBIM)
GlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.
Industry, Sector and Symbol
SymbolOTCMKTS:GBIMPrevious Symbol: NASDAQ:GBIM
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$6.46 million
Price / Sales0.52
Price / CashN/A
Book Value$0.52 per share
Price / Book1.12
Return on EquityN/A
Return on AssetsN/A
Frequently Asked Questions for Globeimmune (OTCMKTS:GBIM)
What is Globeimmune's stock symbol?
Globeimmune trades on the OTCMKTS under the ticker symbol "GBIM."
How were Globeimmune's earnings last quarter?
Globeimmune, Inc. (OTCMKTS:GBIM) released its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter. View Globeimmune's Earnings History.
Who are some of Globeimmune's key competitors?
Some companies that are related to Globeimmune include Mateon Therapeutics (MATN), Strata Skin Sciences (SSKN), Lombard Medical (EVARF), Secure Point Technologies (IMSC), Windtree Therapeutics (WINT), Roka Bioscience (ROKA), NeuroMetrix (NURO), Rosetta Genomics (ROSG), TearLab Corporation (TEAR), Affymax (AFFY), TetraLogic Pharmaceuticals Corporation (TLOG), BG Medicine (BGMD), Delcath Systems (DCTHD), Echo Therapeutics (ECTE), M Pharmaceutical (MPHMF), Imris (IMRSQ) and SINO PHARMACEUT (SBMFF).
Who are Globeimmune's key executives?
Globeimmune's management team includes the folowing people:
- J. William Freytag Ph.D., Independent Chairman of the Board
- Timothy C. Rodell M.D., President, Chief Executive Officer, Director
- C. Jeffrey Dekker CPA, Vice President - Finance, Treasurer, Secretary
- Augustine J. Lawlor, Independent Director
- Daniel J. Mitchell, Independent Director
- S. Edward Torres, Independent Director
How do I buy Globeimmune stock?
Shares of Globeimmune can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globeimmune's stock price today?
One share of Globeimmune stock can currently be purchased for approximately $0.58.
How big of a company is Globeimmune?
Globeimmune has a market capitalization of $3.34 million and generates $6.46 million in revenue each year.
How can I contact Globeimmune?
Globeimmune's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The biopharmaceutical company can be reached via phone at 303-625-2700 or via email at [email protected]
MarketBeat Community Rating for Globeimmune (GBIM)MarketBeat's community ratings are surveys of what our community members think about Globeimmune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Globeimmune (OTCMKTS:GBIM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Globeimmune (OTCMKTS:GBIM)
Analysts' Ratings History for Globeimmune (OTCMKTS:GBIM)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Globeimmune (OTCMKTS:GBIM)
Earnings History by Quarter for Globeimmune (OTCMKTS GBIM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Globeimmune (OTCMKTS:GBIM)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Globeimmune (OTCMKTS:GBIM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Globeimmune (OTCMKTS GBIM)
Insider Ownership Percentage: 23.50%
Insider Trades by Quarter for Globeimmune (OTCMKTS GBIM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/18/2016||Augustine Lawlor||Director||Sell||11,000||$1.55||$17,050.00|| |
|3/17/2016||Daniel J Mitchell||Director||Sell||21,600||$1.66||$35,856.00|| |
|3/15/2016||Daniel J Mitchell||Director||Sell||130,269||$2.26||$294,407.94|| |
|3/11/2016||Augustine Lawlor||Director||Sell||16,500||$1.60||$26,400.00|| |
|3/10/2016||Daniel J Mitchell||Director||Sell||16,400||$1.17||$19,188.00|| |
|3/8/2016||Augustine Lawlor||Director||Sell||15,010||$1.05||$15,760.50|| |
|3/7/2016||Daniel J Mitchell||Director||Sell||11,920||$1.05||$12,516.00|| |
|3/3/2016||Augustine Lawlor||Director||Sell||15,990||$1.11||$17,748.90|| |
|3/2/2016||Daniel J Mitchell||Director||Sell||17,422||$1.02||$17,770.44|| |
|3/1/2016||Daniel J Mitchell||Director||Sell||8,799||$0.96||$8,447.04|| |
|2/29/2016||Augustine Lawlor||Director||Sell||15,000||$0.98||$14,700.00|| |
|2/26/2016||Daniel J Mitchell||Director||Sell||12,501||$1.03||$12,876.03|| |
|2/24/2016||Augustine Lawlor||Director||Sell||15,000||$1.33||$19,950.00|| |
|2/23/2016||Daniel J Mitchell||Director||Sell||22,858||$1.42||$32,458.36|| |
|2/22/2016||Augustine Lawlor||Director||Sell||5,000||$1.43||$7,150.00|| |
|2/19/2016||Ventures Vii Lp Healthcare||Insider||Sell||15,000||$1.44||$21,600.00|| |
|2/18/2016||Daniel J Mitchell||Director||Sell||21,897||$1.45||$31,750.65|| |
|2/16/2016||Ventures Vii Lp Healthcare||Major Shareholder||Sell||15,000||$1.61||$24,150.00|| |
|2/12/2016||Daniel J Mitchell||Director||Sell||3,645||$1.75||$6,378.75|| |
|2/9/2016||Daniel J Mitchell||Director||Sell||7,300||$2.05||$14,965.00|| |
|7/8/2014||Celgene International Inc||Major Shareholder||Buy||200,000||$10.00||$2,000,000.00|| |
|7/8/2014||S. Edward Torres||Director||Buy||85,000||$10.00||$850,000.00|| |
|7/8/2014||Timothy C Rodell Jr||CEO||Buy||5,000||$10.00||$50,000.00|| |
Latest Headlines for Globeimmune (OTCMKTS GBIM)
Globeimmune (OTCMKTS GBIM) Chart for Friday, November, 24, 2017